Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

"I talk to Dave a lot, and he's still on his journey and doing okay," the "Full House" actress tells People The post Candace ...

and response to treatment. The five-year relative survival rate for stage 4 Hodgkin lymphoma is 81 percent, and 64 percent for stage 4 non-Hodgkin lymphoma. Everyday Health follows strict sourcing ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Candace Cameron Bure told PEOPLE in an exclusive interview at the 32nd Annual Movieguide Awards that she often checks in on ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma. Treatment with the CAR-T cell therapy Yescarta ...

Tea planter Vishal Mahindra was twice diagnosed with non-Hodgkin's lymphoma, a type of blood cancer that develops in the ...

“With Qartemi, our flagship CAR T-cell therapy, we aim to transform cancer treatment in India by ... remission of relapsed and refractory Non-Hodgkin Lymphoma, offering hope to patients when ...